Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Firms Can Sue Competitors For Violating Orphan Exclusivity, German Court Rules

Executive Summary

A German civil court has ruled that pharma firms can enforce market exclusivity rights for orphan drugs by taking legal action against competitors. Lawyers say this decision, which relates to Alexion’s Soliris, is the first of its kind and will likely have a wider impact across the EU.

You may also be interested in...

EU Regulatory Reforms Mean Many Orphan Drug Producers Won’t Benefit From Incentives

The EU’s regulatory reform package if unchanged could make orphan drug development less attractive, warn industry representatives.

Amgen Chooses To Settle In US Soliris IPR Tussle

Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.

EU Needs Better Data Tools To Combat Vaccine-Preventable Cancers, Says Industry

Data on vaccine coverage rates and trends in vaccine-preventable disease incidence in the EU are crucial but are often not available or inaccurate, according to EFPIA subgroup Vaccines Europe.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts